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Objective: To determine the serum levels of Th1 (IL-12, IFN-c,TNF-a) and Th2 (IL-5, IL-6 and IL-10) cyto-
kines in childhood-onset SLE, ﬁrst-degree relatives and healthy controls. To elucidate their association
with disease activity, laboratory and treatment features.
Methods: We included 60 consecutive childhood-onset SLE patients [median age 18 years (range 10–37)],
64 ﬁrst-degree relatives [median 40 (range 28–52)] and 57 healthy [median age 19 years (range 6–
30 years)] controls. Controls were age and sex-matched to SLE patients. SLE patients were assessed for
clinical and laboratory SLE manifestations, disease activity (SLEDAI), damage (SDI) and current drug
exposures. Mood and anxiety disorders were determined through Becks Depression (BDI) and Anxiety
Inventory (BAI). Th1 (IL-12, IFN-c,TNF-a) and Th2 (IL-5, IL-6 and IL-10) cytokines levels were measured
by ELISA and compared by non-parametric tests.
Results: Serum TNF-a (p = 0.004), IL-6 (p = 0.007) and IL-10 (p = 0.03) levels were increased in childhood-
onset SLE patients when compared to ﬁrst-degree relatives and healthy controls. TNF-a levels were sig-
niﬁcantly increased in patients with active disease (p = 0.014) and correlated directly with SLEDAI scores
(r = 0.39; p = 0.002). IL-12 (p = 0.042) and TNF-a (p = 0.009) levels were signiﬁcantly increased in patients
with nephritis and TNF-a in patients with depression (p = 0.001). No association between cytokine levels
and SDI scores or medication was observed.
Conclusion: Th1 cytokines may play a role in the pathogenesis of neuropsychiatric and renal manifesta-
tions in childhood-onset SLE. The correlation with SLEDAI suggests that TNF-amay be a useful biomarker
for disease activity in childhood-onset SLE, however longitudinal studies are necessary to determine if
increase of this cytokine may predict ﬂares in childhood-onset SLE.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Systemic lupus erythematosus (SLE) is a chronic, multisystemic
autoimmune disease predominantly affecting women of childbear-
ing age [1]. Approximately 10–20% of all cases of SLE occur in the
ﬁrst two decades of life [1–4]. In childhood-onset patients the fe-
male-to-male ratio is 4:3 with disease onset during the ﬁrst decade
of life, 4:1 during the second decade when compared to 9:1 ratio in
adult-onset SLE [5–7].
Childhood-onset SLE often presents more acute and severe dis-
ease features than adult-onset SLE. Renal (50–67%), neurological
(22–95%) and hematological (77%) involvement, in addition to fe-
ver and lymphadenopathy are more frequently observed in chil-
dren when compared to adult-onset SLE [8–13]. In relation to
disease activity, childhood-onset SLE patients have a more activeedicine, Faculty of Medical
ersitária, Campinas, SP, CEP
. Appenzeller).
sevier OA license.disease not only at disease onset, but also over time when com-
pared to adult-onset SLE [14,15].
The impact of SLE on children is often profound, and a satisfac-
tory outcome in this age group is not a 5 or 10-year survival, but a
survival that more closely approximates the normal lifespan [16].
The awareness that SLE in childhood is a potentially fatal disease,
that atypical presentations are very common, and that aggressive
treatment should be introduced early in the course of the disease,
has signiﬁcantly improved survival in the childhood-onset SLE co-
horts [14–16]. Over the last decades, morbi-mortality rates have
signiﬁcantly dropped in childhood-onset patients in a similar pat-
ter as in adult-onset SLE patients [14,17].
Independently of the age of onset, there is strong evidence sup-
porting the role of cytokine in the pathogenesis of SLE [18].
Although antibody production, driven by Th2 lymphocytes and
immune complex formation are key features in SLE, recent evi-
dences have suggested that Th1 lymphocytes have an important
pathogenic role in SLE [18,19]. The main cytokines associated with
cellular immunity (Th1) are interleukin (IL) 12, interferon gamma
(IFN-c) and tumor necrosis factor alpha (TNF-a), while IL-5, IL-6
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induction of humoral immunity (Th2) [19]. Not only is the cytokine
proﬁle in SLE different when compared to healthy controls, it also
varies according to disease phenotypes and disease activity [18].
Serum IL-12, IFN-c, TNF-a, and IL-5, IL-6 and IL-10 and the rela-
tion between these Th1 and Th2 cytokines have been studied in
adult-onset SLE [19–22]. However, the role of these cytokines in
childhood-onset SLE has never been investigated. The aim of our
study was to determine the serum levels of Th1 (IL-12, IFN-c,
TNF-a) and Th2 (IL-5, IL-6 and IL-10) cytokines in childhood-onset
SLE patients, ﬁrst-degree relatives and healthy controls. In addition
we evaluated their association with disease activity, laboratory and
treatment features.2. Patients and methods
2.1. Subjects
Sixty consecutive childhood-onset SLE patients, recruited from
the Pediatric Rheumatology Outpatient Clinic of State University
of Campinas were included in this study. Patients were included
in the present study if they: (i) fulﬁlled at least four criteria of
American College of Rheumatology (ACR) [23]; (ii) were below
16 years of age at disease onset; and (iii) had a follow-up duration
of at least 6 months.
Sixty-four ﬁrst-degree relatives and 57 healthy controls without
history of any chronic disease (including autoimmune diseases)
were included as a control group. The healthy volunteers were
matched by age and gender to the patients.
This study was approved by the ethics committee at our institu-
tion, and informed written consent was obtained from each partic-
ipant and/or legal guardian.
2.2. Clinical features
All patients had their medical histories, clinical and serological
characteristics evaluated at study entry according to the ACR [23].
Features included in this protocol were age at onset of disease (de-
ﬁned as the age at which the ﬁrst symptoms clearly attributable to
SLE occurred), age at diagnosis (deﬁned as the age when patients
fulﬁlled four or more of the 1982 revised criteria for the classiﬁca-
tion of SLE [23], and follow-up time (deﬁned as the time from dis-
ease onset until May 2010).
All clinical manifestations and laboratory ﬁndings were re-
corded at the day of blood withdrawal. Nephritis was diagnosed
on the basis of proteinuria exceeding 0.5 g/L with abnormal uri-
nary sediment and/or histological ﬁndings. Nephrotic syndrome
was deﬁned as proteinuria in excess of 3.0 g/day. Hematological
alterations were ascribed to lupus only in the absence of bone-
marrow suppression (leukopenia <4000 cells/mm3; thrombocyto-
penia <100,000 cells/mm3; hemolytic anemia). We also analyzed
the presence of malar rash, discoid lesions, subacute cutaneous le-
sions, cutaneous vasculitis, photosensitivity, oral ulcers, arthritis
and serositis. Neurological and psychiatric involvement was de-
ﬁned according to ACR [24].
Treatment prescribed at time of blood withdrawal, as well as its
adverse events related to drug use, was recorded. Doses of oral and
parenteral corticosteroids were analyzed and converted to the
equivalent doses of prednisone.
2.3. Laboratory studies
Antinuclear antibodies (ANAs) were determined by indirect
immunoﬂurescence using HEp-2 cells as substrate, and regarded
as positive if higher than 1:40. Anti-double stranded DNA (dsDNA)antibodies were determined by indirect immunoﬂurescence using
Crithidia as substrate and considered positive if higher than 1:10.
Precipitating antibodies to extractable nuclear antigens (ENAs),
including Ro (SSA), La (SSB), and Sm were detected by a standard-
ized ELISA method, and considered positive if higher than 1:40.
Rheumatoid factor (RF) was detected by nefelometry, and regarded
as positive if higher than 10. Anticardiolipin antibodies (aCL) of the
IgG and IgM isotypes were measured by an ELISA method [25]. The
lupus anticoagulant (LA) activity was detected by coagulation as-
says in platelet-free plasma obtained by double centrifugation, fol-
lowing the recommendation of the subcommittee on LA of the
Scientiﬁc and Standardization Committee of the International Soci-
ety of Thrombosis and Homeostasis [26]. These measurements
were carried out twice, at an interval of 12 weeks.2.4. Disease activity and damage
Disease activity was measured by the Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI) [27]. SLEDAI scores range
between 0 and 105. Scores of P3 were considered active disease
[28]. Active nephritis was diagnosed on the basis of renal items
of the SLEDAI (proteinuria exceeding 0.5 g/L, abnormal urinary
sediment, low complement levels).
Cumulative SLE-related damage in all patients was determined
using the Systemic Lupus International Collaborating Clinics (SLIC-
Cs)/ACR Damage Index (SDI) [29] at time of blood withdrawal. SDI
score range from 0 to 47. Damage was considered if scoresP1 [29].2.5. Mood and anxiety evaluation
All subjects completed the Beck Depression (BDI) [30] and Beck
Anxiety Inventory (BAI) [31] at study entry. For patients under
16 years old, Children’s Depression Inventory (CDI) was applied.
These scales consist of 21 items, each describing a common symp-
tom of depression/anxiety. The respondent is asked to rate how
much he or she has been bothered by each symptom over the past
month on a 4-point scale ranging from 0 to 3. The items are
summed to obtain a total score that can range from 0 to 63. The
cutoffs used for the BDI are: 0–13: no/minimal depression; 14–
19: mild depression; 20–28: moderate depression; and 29–63: se-
vere depression and for the BAI: 0–7: no/minimal level of anxiety;
8–15: mild anxiety; 16–25: moderate anxiety; 26–63: severe anx-
iety. The cutoff used for CDI is 17.2.6. Cytokines assays
A blood sample was collected from all participants, centrifuged
at 3000 rpm for 15 min after being allowed to clot for 30 min at
room temperature. Sera were separated as soon as possible from
the clot of red cells after centrifugation to avoid TNF-a production
by blood cells that falsely could increase its values [32]. Separated
sera were kept in aliquots at 80 C until the time of assay. None of
the samples was taken during an episode of a severe bacterial
infection requiring hospitalization because TNF-a could be in-
creased due to a secondary cause [33]. The samples were per-
formed in duplicate to guarantee the reproducibility of the kits.
Commercially available kits from R&D Systems (London, UK)
were used for the measurement of serum IFN-c, TNF-a, IL-5, 6,
10 and 12 levels by enzyme-linked immunosorbent assay (ELISA),
carried out in accordance with the manufacturer’s instructions. The
minimum detectable dose (MDD) was 8.0 pg/mL for IFN-c, 0.29 pg/
mL for IL-5, 0.039 pg/mL for IL-6 and 3.9 pg/mL for IL-10. For IL-12,
MDD was 0.5 pg/mL. Assay sensitivity was 0.106 pg/ml for TNF-a.
Table 2
Clinical, laboratory and treatment features at day of blood
withdrawal.
Manifestations Patients, N = 60
Clinical features
Alopecia 3 (5%)
Malar rash 4 (6.6%)
Nephritis 20 (33.3%)
Neurologic manifestations 21 (35%)
Serositis 2 (3.3%)
Vasculitis 3 (5%)
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All statistical analyses were performed using SPSS Statistics
software version 17.0 and results were given as median and range.
Kruskal–Wallis Test was used to compare cytokines levels between
groups. Spearman’s correlation was used to correlate continuous
variables (e.g. cytokines levels and SLEDAI, SDI, BDI and BAI
scores). Cytokine levels and categorical variables were compared
by Mann–Whitney U test. For all analyses, a p-value < 0.05 was
considered statistically signiﬁcant.Laboratory features
Anticardiolipine or LA 13 (21.6%)
Anti-SM 9 (15%)
Anti-SSA/Ro 8 (13.3%)
dsDNA 25 (41.6%)
Leukopenia 2 (6.7%)
Thrombocytopenia 2 (6.7%)
Treatment
No medication 8 (13.3%)
Prednisone 42 (70%)
Hydroxychloroquine 32 (53.3%)
Immunosuppressive drugs 29 (48.3%)
Azathioprine 15 (25%)
Ciclophosphamide 2 (3.3%)
Cyclosporine 5 (8.3%)
Methotrexate 1 (1.6%)
Mycophenolate mofetil 6 (10%)3. Results
3.1. Demographics
We included 60 consecutive childhood-onset SLE patients.
Fifty-seven (95%) were female with a median age of 18 years
(range 10–37). The median of the disease duration was 4 years
(range 0–26 years). Sixty-four ﬁrst-degree relatives [59 women;
mean age of 40 years (range 28–52)] agreed to participate in the
study. The control group consisted of 57 healthy controls (52
women) with a median age of 19 years (range 6–30 years). Patients
and healthy controls were statistically comparable in terms of age
and sex (Table 1).dsDNA: double-stranded DNA, LA: lupus anticoagulant3.2. Clinical, laboratory, and treatment features
All patients had disease onset before the age of 16 and clinical
and laboratory manifestations at disease onset are shown in Ta-
ble 2. At time of study entry, 30 (50%) childhood-onset SLE patients
had active disease (SLEDAIP3) with median SLEDAI scores of 8
(range 4–18). The 30 (50%) inactive patients had a median SLEDAI
score of 0 (range 0–2). Active nephritis (33.3%), new malar rash
(6.6%), new alopecia (5.0%) and cutaneous vasculitis (5.0%) were
the clinical manifestations more frequently observed (Table 2).
At time blood withdrawal, 8 (13.3%) patients were not taking
any immunosuppressant medication. Forty-two (70%) patients
were receiving prednisone, 32 (53.3%) hydroxychloroquine and
22 (36.6%) patients were receiving other immunosuppressive
drugs (Table 2).
Depression was identiﬁed in 10 (16.7%) patients and in no
healthy control or ﬁrst-degree relatives. Mild depression was
identiﬁed in 5 (8.3%) patients and 5 (8.3%) patients had
moderate/severe depression. Anxiety was observed in 21 (35%)
childhood-onset SLE patients. Twelve (20%) patients had mild
and 9 (15%) had moderate/severe anxiety.Table 1
Demographic and clinical characteristics of patients and controls included i
Parameter Childhood-onset SLE patients
N = 60
Sex
Female 57 (95%)
Age (years) 18 (range 10–37)
Disease duration (years) 4 (range 0–26)
SLEDAI 2 (range 0–18)
Active disease N = 30 8 (range 4–18)
Inactive disease N = 30 0 (range 0–2)
SDI 0 (range 0–3)
a P 6 0.05.3.3. Cytokines assays
Serum levels of Th1 cytokines and Th2 cytokines, in SLE patients
are shown in Fig. 1. Sera TNF-a (p = 0.004), IL-6 (p = 0.007) and IL-
10 (p = 0.03) levels were signiﬁcantly increased in childhood-onset
SLE when compared to ﬁrst-degree relatives and healthy controls
(Table 3). No signiﬁcant difference in serum TNF-a, IL-6 and IL-
10 levels was observed between ﬁrst-degree relatives and healthy
controls. No signiﬁcant difference in serum levels of IFN-c, IL-5 and
IL-12 was observed among childhood-onset SLE, ﬁrst-degree rela-
tives and healthy controls. TNF-a levels (p = 0.014) were signiﬁ-
cantly increased in patients with active disease (SLEDAIP3)
when compared to patients with inactive disease. In addition,
TNF-a levels correlated directly with SLEDAI scores (r = 0.39;
p = 0.002). Although IL-6 was increased in patients with active dis-
ease when compared to patients with inactive disease, no statisti-
cally signiﬁcance was noted.
IL-12 (p = 0.042) and TNF-a (p = 0.009) levels were signiﬁcantly
increased in patients with active nephritis when compared to pa-
tients without nephritis. IL-6 levels were signiﬁcantly increasedn the study.
First-degree relatives Healthy controls
N = 64 N = 57
59 (92.18%) 52 (91.22%)
40 (range 28–52)a 19 (range 6–30)
– –
– –
– –
Fig. 1. Sera Th1 and Th2 cytokine levels of childhood-onset SLE patients and healthy controls.
Table 3
Sera cytokines levels of the individuals included in the study.
Sera levels (pg/mL) Childhood-onset SLE patients, N = 60 First-degree relatives, N = 64 Healthy controls, N = 57
Th1 cytokines
IL-12 median (range) 1.54 (0.58–48.79) 1.38 (0.5–5.77) 1.38 (0.74–9.76)
IFN-c 11.36 (8.1–36.88) 11.7 (6.76–26.43) 13.39 (8.08–30.08)
TNF-a 2.18 (0.8–11.17)a 1.63 (0.21–9.65) 1.30 (0.25–12.53)
Th2 cytokines
IL-5 2.5 (0.61–12.59) 2.76 (0.33–8.78) 3.29 (0.49–8.86)
IL-6 1.5 (0.22–13.98)a 1.45 (0.56–13.84) 0.98 (0.39–13.29)
IL-10 14 (3.93–57)a 10.7 (3.91–24.94) 6.01 (2.24–20.99)
a P 6 0.05.
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tients with positive dsDNA (p = 0.01). An indirect correlation be-
tween the TNF/IL-10 ratio and dsDNA was observed (r = 0.45;
p = 0.001).
TNF-a levels were signiﬁcantly increased in patients with
depression moderate/severe (p = 0.01) when compared to patients
without depression. IL-10 levels had a negative correlation with
the severity of depression (r = 0.45; p = 0.013).
No association between other SLEDAI variables or SDI scores
and IL-12, IFN-c, TNF-a, IL-5, IL-6 and IL-10 levels was observed.
In addition, no difference in these cytokine levels in patients with
and without medication was observed.
4. Discussion
Cytokines are low-weight proteins that play a key role in immu-
nological dysregulation observed in autoimmune diseases. The
development of SLE can be viewed as Th1 and Th2 imbalance.
The increased levels of proinﬂammatory cytokines are believed
to play a key role in the pathogenesis of SLE [34–47]. Higher cyto-
kine levels in SLE patients may promote inﬂammatory response,
apoptosis and autoantibody production that not only initiate, but
may also maintain SLE disease activity over time [34,41,42,44,46].
In our study, we observed increased TNF-a, IL-6 and IL-10 levels
in childhood-onset SLE when compared to healthy controls andﬁrst-degree relatives, as previously observed in adult-onset SLE pa-
tients [18–22,48–54].
Although several studies have analyzed TNF-a levels in adult-
onset SLE patients, the clinical signiﬁcance is less clear
[19,20,48,50–54]. In addition to increased TNF-a levels in patients
with active disease, we observed a positive correlation between
SLEDAI scores, suggesting that TNF-a could be a biomarker for
disease activity in SLE. Several studies [19,50–52,54] analyzing
adult-onset SLE have shown higher TNF-a levels in SLE patients
with active disease. However, this association was never studied
in a childhood-onset cohorts.
We also observed signiﬁcantly higher levels of TNF-a in patients
with nephritis when compared to patients without nephritis. SLE
nephritis is a prototype of immune-complex induced kidney dam-
age [55]. In SLE nephritis, the pattern of glomerular injury is pri-
marily related to dsDNA and anti-C1q antibodies and the
formation of immune complexes. These immune complexes are
deposited on the tissue surface, inducing inﬂammatory response
by activating adhesion molecules on endothelium. This response
leads to the recruitment of pro inﬂammatory leukocytes. Renal in-
jury results from activated and damaged glomerular cells, inﬁltrat-
ing macrophages, and cytokines [56].
Recently, it has been shown that dysregulated apoptosis is also
an important factor for developing proliferative lupus nephritis
[54,57]. Higher TNF-a levels were also observed in one previous
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[20], and in other non-SLE nephropathies, including membranous
nephropathies and nephritic syndromes [58,59]. These ﬁndings
support the hypothesis that TNF-a may play a pathogenic role in
the induction or maintenance of glomerular barrier dysfunction
in renal diseases [59].
The involvement of TNF-a in lupus nephritis is further sup-
ported by the improvement of lupus nephritis under TNF-a
blocking therapy [60–65]. In particular, nephritis may remain in
long-term remission after just a few infusions of inﬂiximab [64].
Although an increase in the autoantibody response to chromatin
was observed in patients treated with TNF-a blocking therapy,
these were transient and without pathologic consequences [66].
It is important to consider some limitations of the study analyzing
TNF-a blocking therapy, such as the small number of SLE patients
included (seven patients) and the short follow up period (4–
10 weeks) [63].
It is important to stress that no controlled trials about TNF-a
blocking therapy have been published and that the number of pa-
tients treated is still very limited [61,65]. Therefore, no ﬁrm con-
clusions can be drawn. Nevertheless, the available studies are of
interest in that they not only provide a rationale for controlled tri-
als, but also add to our understanding of the role of TNF-a in the
pathophysiology of SLE [67].
We also detected higher levels of IL-12 in patients with nephri-
tis. Previous studies have demonstrated that increased IL-12 pro-
duction was associated closely with renal disease in parallel with
Th1 polarization and increased IFN-c solubilization in vitro
[68,69]. In addition, the increase in urinary IL-12 apparently re-
ﬂected both its serum and its glomerular accumulation [68,69].
Recently, it has been shown that nutrition may contribute to re-
nal disorders in SLE. Dietary factors that suppress Th2 cytokines
such as IL-4 at early phase, and inhibit inﬂammatory cytokines
IL-1b, IL- 6, TNF-a and IFN-c, and enhance TGF-b or IL-10 produc-
tion at late phase, are beneﬁcial for delay onset of proteinuria and
for longer life span of murine lupus [70]. However, we did not eval-
uate the diet of the individuals included in our study.
IL-10 boosts B cell proliferation and immunoglobulin class
switching resulting in enhanced antibody secretion with the capac-
ity to enter extravascular compartments and promote inﬂamma-
tion in SLE [42,44]. In SLE patients, it has been shown that
elevated production of IL-10 is capable of promoting generation
of dsDNA antibodies [71], as observed in our study. Although SSA
and SSB were also reported to be associated with high TNF/low
IL-10 genotype [72], we did not ﬁnd such association in our cohort.
In addition, IL-6 was demonstrated to be highly expressed in kid-
neys and to be signiﬁcantly increased in the serum SLE patients
with nephritis [20]. We did not ﬁnd an association between IL-6
and nephritis; however we observed that patients with dysmor-
phic hematuria had increased serum levels of IL-6.
Although depression was identiﬁed in only 17% of our cohort,
we observed increased levels of TNF-a in patients with moder-
ate/severe depression when compared to patients with no/mild
depression.
In the past 20 years since the initial reports of neural-immune
interactions in depression, several studies have shown a clear asso-
ciation between activation of the immune system, levels of proin-
ﬂammatory cytokines, and psychiatric symptoms [73–75]. TNF-a
exerts its biological effect mainly by binding to tumor necrosis fac-
tor receptor 1 (TNFR1) and receptor 2 (TNFR2), causing activation
of complex signaling cascades that mediate different intracellular
effects [76]. In the brain, TNFR1 seems to show a constitutive pat-
tern of expression whereas TNFR2 is mainly expressed under stim-
ulatory conditions [76]. The highest concentrations of TNF-a
receptors in the brain are found in several regions involved in
mood regulation and cognitive functioning like the hypothalamus,hippocampus, and areas of the cerebral cortex [77]. Although an
associative link between neuroinﬂammation and mood disorders
is widely accepted, further studies are necessary to establish the
cause-effect relationship [78]. Several studies connect cytokines
with the pathogenesis of depression in Alzheimer’s disease [79],
in atypical depression [80], in major depressive disorder [73–
75,81,82], and in multiple sclerosis [72], however this association
has not been reported in SLE so far.
We did not observed correlation between depression and other
cytokines studied, however we found a negative correlation be-
tween IL-10 levels and the severity of depression. There is no data
in the literature exploring this correlation between depression and
IL-10 levels so far.
Hydroxychloroquine has been shown to reduce the probability
of ﬂares, the accrual of damage, to possibly protect patients with
SLE from the occurrence of vascular and thrombotic events and
even to increase survival [83]. Literature data suggests that anti-
malarials interfere with TNF-a release from human and murine
cells, although their exact mode of action is not fully understood
[34]. In one previous study [34] chloroquine was shown to lower
TNF-a levels, however in our study we did not observe differences
in TNF-a levels between hydroxychloroquine users and non-users.
The pathogenesis of SLE is a combination of multifactorial, ge-
netic and environmental inﬂuences, which lead to an irreversible
break in immunologic self-tolerance [83]. SLE family members
are at higher risk of developing not only SLE, but also other autoim-
mune diseases [84–86]. However, IL-12, IFN-c, TNF-a, IL-5, IL-6
and IL-10 levels have never been studied in ﬁrst-degree relatives.
In our study we did not observe any difference in these cytokine
levels of ﬁrst-degree relatives when compared to healthy controls.
To the best of our knowledge, this is the ﬁrst study to evaluate
Th1 (IL-12, IFN-c, TNF-a) and Th2 (IL-5, IL-6 and IL-10) cytokines in
childhood-onset SLE. Th1 cytokines may play a role in the patho-
genesis of neuropsychiatric and renal manifestations in child-
hood-onset SLE. The correlation with SLEDAI suggests that TNF-a
may be a useful biomarker for disease activity in childhood-onset
SLE, however longitudinal studies are necessary to determine if in-
crease of this cytokine may predict ﬂares in childhood-onset SLE.Acknowledgments
Fundação Amparo À Pesquisa Estado São Paulo-Brasil (FAPESP
2008/02917-0 and 2009/06049-6 and 2009/11076-2), Conselho
Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/2009-4).References
[1] Papadimitraki ED, Isenberg DA. Childhood- and adult-onset lupus: an update
of similarities and differences. Expert Rev Clin Immunol 2009;5:391–403.
[2] Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in
childhood. Rheum Dis Clin N Am 2002;28:561–77.
[3] Stichweh D, Arce E, Pascual V. Update on pediatric systemic lupus
erythematosus. Curr Opin Rheumatol 2004;16:577–87.
[4] Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult and childhood-onset
systemic lupus erythematosus: a comparison of onset, clinical features,
serology and outcome. Br J Rheum 1995;34:866–72.
[5] Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus
erythematosus: a comparison of worldwide disease burden. Lupus
2006;15:308–18.
[6] Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic
diseases: results from the Canadian Pediatric Rheumatology Association
Disease Registry. J Rheumatol 1996;23:1981–7.
[7] McCarty DJ, Manzi S, Medsger Jr TA, Ramsey-Goldman R, LaPorte RE, Kwoh CK.
Incidence of systemic lupus erythematosus Race and gender differences.
Arthritis Rheum 1995;38:1260–70.
[8] Mina R, Brunner HI. Pediatric lupus-are there differences in presentation,
genetics, response to therapy, and damage accrual compared with adult lupus?
Rheum Dis Clin North Am. 2010;36:53–80.
[9] Font J, Cervera R, Espinosa G, Pallarés L, Ramos-Casals M, Jiménez S, et al.
Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and
790 M. Postal et al. / Cytokine 61 (2013) 785–791immunological ﬁndings in 34 patients and comparison with SLE characteristics
in adults. Ann Rheum Dis 1998;57:456–9.
[10] Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L,
et al. Juvenile-onset systemic lupus erythematosus: different clinical and
serological pattern than adult-onset systemic lupus erythematosus. Ann
Rheum Dis 2009;68:412–5.
[11] Sibbitt Jr WL, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, et al.
The incidence and prevalence of neuropsychiatric syndromes in pediatric
onset systemic lupus erythematosus. J Rheumatol 2002;29:1536–42.
[12] Carreno L, Lopez-Longo FJ, Monteagudo I, Rodríguez-Mahou M, Bascones M,
González CM, et al. Immunological and clinical differences between
juvenile and adult onset of systemic lupus erythematosus. Lupus 1999;8:
287–92.
[13] Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED. Difference in
disease features between childhood-onset and adult-onset systemic lupus
erythematosus. Arthritis Rheum 2008;58:556–62.
[14] Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset
systemic lupus erythematosus: a comparison of onset, clinical features,
serology, and outcome. Br J Rheumatol 1995;34:866–72.
[15] Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al.
Differences in long-term disease activity and treatment of adult patients with
childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum
2009;61:13–20.
[16] Appenzeller S, Marini R, Costallat LT. Damage did not independently inﬂuence
mortality in childhood systemic lupus erythematosus. Rheumatol Int.
2005;25:619–24.
[17] von Scheven E, Bakkaloglu A. What’s new in paediatric SLE? Best Pract Res Clin
Rheumatol 2009;23:699–708.
[18] Yap DY, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus
erythematosus: from basics to recent advances. J Biomed Biotechnol
2010;2010:365083.
[19] Gómez D, Correa PA, Gómez LM, Cadena J, Molina JF, Anaya JM. Th1/Th2
cytokines in patients with systemic lupus erythematosus: is tumor necrosis
factor alpha protective? Semin Arthritis Rheum 2004;33:404–13.
[20] Sabry A, Elbasyouni SR, Sheashaa HA, Alhusseini AA, Mahmoud K, George SK,
et al. Correlation between levels of TNF-alpha and IL-6 and hematological
involvement in SLE Egyptian patients with lupus nephritis. Int Urol Nephrol
2006;38:731–7.
[21] Mellor-Pita S, Citores MJ, Castejon R, Yebra-Bango M, Tutor-Ureta P, Rosado S,
et al. Monocytes and T lymphocytes contribute to a predominance of
interleukin 6 and interleukin 10 in systemic lupus erythematosus.
Cytometry B Clin Cytom 2009;76:261–70.
[22] Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels
correlated with disease activity in systemic lupus erythematosus. Clin Exp
Rheumatol 1998;16:283–8.
[23] Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothﬁeld NF, et al. The 1982
revised criteria for the classiﬁcation of systemic lupus erythematosus. Arthritis
Rheum 1982;25:1271–7.
[24] ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The
American College of Rheumatology nomenclature and case deﬁnitions for
neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599–608.
[25] Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin
antibody test: report of an international workshop held 4 April 1986. Clin Exp
Immunol 1987;68:215–22.
[26] Brandt JT, Triplett DA, Alving B, Scharrer I. On behalf of the Subcommittee on
Lupus Anticoagulant/Antiphospholipid Antibody of the Scientiﬁc and
Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus
anticoagulants: an update. Thromb Haemost 1995;74:1185–90.
[27] Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the
SLEDAI. A disease activity index for lupus patients. The Committee on
Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.
[28] Yee CS, Farewell VT, Isenberg DA, Grifﬁths B, Teh LS, Bruce IN, et al. The use of
Systemic Lupus Erythematosus Disease Activity Index-2000 to deﬁne active
disease and minimal clinically meaningful change based on data from a large
cohort of systemic lupus erythematosus patients. Rheumatology (Oxford)
2011;50:982–8.
[29] Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al.
The reliability of the Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index in patients with systemic
lupus erythematosus. Arthritis Rheum 1997;40:809–13.
[30] Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for
measuring depression. Arch Gen Psychiatry 1961;4:561–71.
[31] Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical
anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893–7.
[32] Leroux-Roels G, Offner F, Philippe J, Vermeulen A. Inﬂuence of blood collecting
systems on concentrations of tumor necrosis factor in serum and plasma. Clin
Chem 1988;134:2373–4.
[33] Galley HF, Webster NR. The immuno-inﬂammatory cascade. Br J Anaesth
1996;77:11–6.
[34] Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A.
Chloroquine treatment inﬂuences proinﬂammatory cytokine levels in
systemic lupus erythematosus patients. Lupus 2006;15:268–75.
[35] Trinchieri G. Interleukin-12 and the regulation of innate resistance and
adaptive immunity. Nat Rev Immunol 2003;3:133–46.
[36] Trinchieri G. Interleukin-12: a cytokine at the interface of inﬂammation and
immunity. Adv Immunol 1998;70:83–243.[37] Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and
its receptor. Annu Rev Immunol 1993;11:571–611.
[38] Joseph A, Brasington R, Kahl L, Ranganathan P, Cheng TP, Atkinson J.
Immunologic rheumatic disorders. J Allergy Clin Immunol 2010;125:S204–15.
[39] Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumor necrosis
factor and receptors in models of multi-organ inﬂammation, rheumatoid
arthritis, multiple sclerosis and inﬂammatory bowel disease. Ann Rheum Dis
1999;58:132–9.
[40] Bradley JR. TNF-mediated inﬂammatory disease. J Pathol 2008;214:149–60.
[41] Wen X, Zhang D, Kikuchi Y, Jiang Y, Nakamura K, Xiu Y, et al. Transgene-
mediated hyper-expression of IL-5 inhibits autoimmune disease but increases
the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Eur
J Immunol 2004;34:2740–9.
[42] Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal anti-double-stranded DNA
autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-
10 and TNF-alpha from normal human mononuclear cells involving in the
lupus pathogenesis. Immunology 2000;99:352–60.
[43] Battaglia M, Gianfrani C, Gregori S, Roncarolo MG. IL-10-producing T
regulatory type 1 cells and oral tolerance. Ann NY Acad Sci 2004;1029:142–53.
[44] Gerli R, Nocentini G, Alunno A, Bocci EB, Bianchini R, Bistoni O, et al.
Identiﬁcation of regulatory T cells in systemic lupus erythematosus.
Autoimmun Rev 2009;8:426–30.
[45] Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T
regulatory cells. Immunol Rev 2001;182:68–79.
[46] Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory T cells (Tr1) in autoimmunity.
Semin Immunol 2011;23:202–8.
[47] Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-
term antigen-speciﬁc anergic state in human CD4+ T cells. J Exp Med
1996;184:19–29.
[48] Al-Mutairi S, Al-Awadhi A, Raghupathy R, Al-Khawari H, Sada P, Al-Herz A,
et al. Lupus patients with pulmonary involvement have a pro-inﬂammatory
cytokines proﬁle. Rheumatol Int 2007;27:621–30.
[49] Sabry AA, Elbasyouni SR, Kalil AM, Abdel-Rahim M, Mohsen T, Sleem A.
Markers of inﬂammation and atherosclerosis in Egyptian patients with
systemic lupus erythematosus. Nephrology (Carlton) 2006;11:329–35.
[50] Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK,
et al. Proinﬂammatory cytokines (TNF-alpha and IL-6) in Egyptian patients
with SLE: its correlation with disease activity. Cytokine. 2006;35:148–53.
[51] Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, et al.
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus
erythematosus are signiﬁcantly higher than in other rheumatic diseases and
correlate with disease activity. J Rheumatol 1997;24:303–8.
[52] Mahmoud RA, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis
factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and
disease activity in Egyptian female patients with systemic lupus
erythematosus. Clin Biochem 2005;38:134–41.
[53] Jones BM, Liu T, Wong RW. Reduced in vitro production of interferon-gamma,
interleukin-4 and interleukin-12 and increased production of interleukin-6,
interleukin-10 and tumour necrosis factor-alpha in systemic lupus
erythematosus. Weak correlations of cytokine production with disease
activity. Autoimmunity 1999;31:117–24.
[54] Studnicka-Bencke A, Steiner G, Petera P, Smolen JS. Tumor necrosis factor
alpha and its soluble receptors parallel clinical disease and autoimmune
activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067–74.
[55] Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, et al.
Predominance of Th1 immune response in diffuse proliferative lupus nephritis.
Arthritis Rheum 2001;44:2097–106.
[56] Gigante A, Gasperini ML, Afeltra A, Barbano B, Margiotta D, Cianci R, et al.
Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci
2011;15:15–24.
[57] Gloor JM. Lupus nephritis in children. Lupus 1998;7:639–43.
[58] Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, KimMJ. Circulating factors in sera or
peripheral blood mononuclear cells in patients with membranous
nephropathy or diabetic nephropathy. J Korean Med Sci 1997;12:539–44.
[59] Lionaki S, Siamopoulos K, Theodorou I, Papadimitraki E, Bertsias G, Boumpas D,
et al. Inhibition of tumour necrosis factor alpha in idiopathic membranous
nephropathy: a pilot study. Nephrol Dial Transplant 2009;24:2144–50.
[60] Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus
erythematosus. Ann Rheum Dis 2000;59:243–51.
[61] Aringer M, Smolen JS. Efﬁcacy and safety of TNF-blocker therapy in systemic
lupus erythematosus. Expert Opin Drug Saf 2008;7:411–9.
[62] Aringer M, Smolen JS. Tumor necrosis factor and other proinﬂammatory
cytokines in systemic lupus erythematosus: a rationale for therapeutic
intervention. Lupus 2004;13:344–7.
[63] Aringer M, Steiner G, Graninger WB, Höﬂer E, Steiner CW, Smolen JS. Effects of
short-term inﬂiximab therapy on autoantibodies in systemic lupus
erythematosus. Arthritis Rheum 2007;56:274–9.
[64] Zhu LJ, Yang X, Yu XQ. Anti-TNF-alpha therapies in systemic lupus
erythematosus. Biomed Biotechnol 2010;2010:465898.
[65] Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new
therapeutic approach for systemic lupus erythematosus. An update upon
efﬁcacy and adverse events. Autoimmune Rev 2011;11:56–60.
[66] Mageed RA, Isenberg DA. Tumors necrosis factor alpha in systemic lupus
erythematosus and anti-DNA autoantibody production. Lupus 2002;11:850–5.
[67] Aringer M, Smolen JS. Therapeutic blockade on TNF in patients with SLE-
promising or crazy? Autoimmune Rev 2012;11:321–5.
M. Postal et al. / Cytokine 61 (2013) 785–791 791[68] Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Overexpression of
interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp
Immunol 2008;154:247–54.
[69] Nagai T, Yanagida T, Hirohata S. Anti-ribosomal P protein antibody induces
Th1 responses by enhancing the production of IL-12 in activated monocytes.
Mod Rheumatol 2011;21:57–62.
[70] Hsieh CC, Lin BF. Dietary factors regulate cytokines in murine models of
systemic lupus erythematosus. Autoimmun Rev. 2011;11:22–7.
[71] López P, Gómez J, Prado C, Gutiérrez C, Suárez A. Inﬂuence of functional
interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-
alpha, IL-10, and regulatory T cell population in patients with systemic lupus
erythematosus receiving antimalarial treatment. J Rheumatol 2008;35:
1559–66.
[72] Suárez A, López P, Mozo L, Gutiérrez C. Differential effect of IL10 and TNF-a
genotypes on determining susceptibility to discoid and systemic lupus
erythematosus. Ann Rheum Dis 2005;64:1605–10.
[73] Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor
necrosis factor alpha concentrations in major depression and multiple
sclerosis. Eur Neuropsychopharmacol 2001;11:203–8.
[74] Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis
factor-alpha levels and treatment response in major depressive disorder.
Psychopharmacology (Berl) 2003;170:429–33.
[75] Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-
analysis of cytokines in major depression. Biol Psychiatry 2010;67:446–57.
[76] Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives.
Trends Cell Biol 2001;11:372–7.
[77] Khairova RA, Machado-Vieira R, Du J, Manji HK. A potential role for pro-
inﬂammatory cytokines in regulating synaptic plasticity in major depressive
disorder. Int J Neuropsychopharmacol 2009;12:561–78.[78] Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-like
behavior induced by tumor necrosis factor-a in mice. Neuropharmacology
2012;62:419–26.
[79] Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease.
Pharmacol Ther 2010;128:519–48.
[80] Yoon HK, Kim YK, Lee HJ. Role of cytokines in atypical depression. Nord J
Psychiatry 2012;66:183–8.
[81] Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al.
Depression, comorbidities and the TNF-alpha system. Eur Psychiatry
2008;23:421–9.
[82] Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the
pathophysiology of major depressive disorder. Prog Neuropsychopharmacol
Biol Psychiatry 2007;31:1044–53.
[83] Alarcón GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, et al.
LUMINA study group. Effect of hydroxychloroquine on the survival of patients
with systemic lupus erythematosus: data from LUMINA, a multiethnic US
cohort (LUMINA L). Ann Rheum Dis 2007;66:1168–72.
[84] Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha
activity is a heritable risk factor for systemic lupus erythematosus. Genes
Immunol 2007;8:492–502.
[85] Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Age- and sex-
related patterns of serum interferon-alpha activity in lupus families. Arthritis
Rheum 2008;58:2113–9.
[86] Scoﬁeld RH, Bruner GR, Harley JB, Namjou B. Autoimmune thyroid disease is
associated with a diagnosis of secondary Sjogren’s syndrome in familial
systemic lupus. Ann Rheum Dis 2007;66:410–3.
